COVID, Volume 2, Issue 4

In November of 2021, a recently evolved variant of SARS-CoV-2, omicron, was discovered. In just one month, omicron has spread to more than 89 countries resulting in a rapid rise in cases and a new wave of infections. With over 46 mutations, omicron b...

Public trust in governmental policies concerning public health measures is often now questioned. This is an acute problem with respect to vaccinations and particularly true regarding concerns around vaccination of children. Vaccination against COVID-...

The ongoing COVID-19 pandemic remained a major public health concern despite a large-scale deployment of vaccines. One of the vaccines is CoronaVac, an inactivated vaccine. The efficacy of the vaccine was estimated at 50.7–83.5% in clinical tri...

The availability of accurate information has proved fundamental to managing health crises. This research examined pandemic data provided by 198 countries worldwide two years after the outbreak of the deadly Coronavirus in Wuhan, China. We compiled an...

During the SARS-CoV-2 (COVID-19) pandemic, the immunogenicity of the virus for various autoimmune complications has been observed. To date, a few reports have been published that raise the possibility of new onset myasthenia gravis (MG) associated wi...

Since 2019, COVID-19 began spreading globally and has significantly affected peoples’ daily lifestyles. The public was asked to stay at home for constant quarantine and community containment starting on 23 January 2020. To assess the circadian...

Gut microflora dysbiosis affects the majority of individuals after COVID-19, contributing to both gastro-intestinal (GI) and non-GI symptoms. Natural phytochemicals have reported anti-viral properties and favourable effects on inflammatory and oxidat...